UCSF

Tagged: School of Pharmacy

QBI fellowship fosters curiosity and perseverance for women scientists

Mon Jan 28, 2019
Kyosiimire-Lugemwa
Credit: 
QBI

Jacqueline Kyosiimire-Lugemwa, PhD, was the first recipient of QBI's Scholarship for Women from Developing Nations in Biosciences. 

Jacqueline Kyosiimire-Lugemwa, the first recipient of QBI’s Scholarship for Women from Developing Nations in Biosciences, spent a year at UCSF in which her perseverance in the sciences was tested. She recently returned to her home country of Uganda more ready than ever to tackle big questions about HIV.

Federal shutdown cancels CERSI conference aimed at health care cooperation

Federal shutdown cancels conference aimed at health care cooperation
Fri Jan 4, 2019
San Francisco Business Times

CRISPR-based obesity treatment shows promise for other diseases

Thu Jan 17, 2019
Ahituv, right, works in his lab with postdoc Fumitaka Inoue
Credit: 
Susan Merrell

Nadav Ahituv, PhD, right, was able to curb obesity in mice by tweaking two genes involved in controlling appetite.

A recent study by Nadav Ahituv, PhD, showed that obesity caused by a gene mutation could be treated in animal models.

COSA Winter Auction

Wed Feb 20, 2019 - 4:30 pm to 8:00 pm

Fraser appointed to Bowes Biomedical Investigator Program

Wed Jan 9, 2019
Fraser stands in front of a whiteboard
Credit: 
Elisabeth Fall

James Fraser, PhD, developed new ways of doing crystallography over a wide range of temperatures.

Fraser developed several new tools for creating maps of macromolecules, a critical first step for finding new drugs.

Keiser receives $2.5 million to apply machine learning towards new therapies for Alzheimer’s, Parkinson’s

Tue Jan 8, 2019
Keiser
Credit: 
UCSF

Michael Keiser, PhD, received a Ben Barres Early Career Acceleration Award from the Chan Zuckerberg Initiative, which will support his research into novel therapies for neuro­de­gener­a­tion.

Michael Keiser, PhD, received a Ben Barres Early Career Acceleration Award from the Chan Zuckerberg Initiative, which will fund his research into novel therapies for neurodegeneration.

Combination drug therapy overcomes drug-resistant lung cancer in the lab

Wed Dec 19, 2018
Chest x-ray, showing a possible lung cancer tumor.
Credit: 
National Cancer Institute

A chest x-ray showing a possible lung cancer tumor (National Cancer Institute)

Many types of lung cancer thwart even the most targeted of therapies due to drug resistance, but a group of UCSF scientists led by Sourav Bandyopadhyay, PhD, have now shown that adding a second drug into treatment regimens can overcome this resistance in lab-grown, lung cancer cell lines.

Paul R. Ortiz de Montellano elected a fellow of the Royal Society of Chemistry

Mon Dec 17, 2018
Ortiz de Montellano
Credit: 
Majed Abolfazli

Paul Ortiz de Montellano, PhD, is an expert on P450 enzymes and his latest work looks at their role in tuberculosis infections.

Ortiz de Montellano gained renown for his work with cytochrome P450 enzymes, which help the liver metabolize drugs and other chemicals, and regulate hormone levels.

QBI scientists decipher how Ebola, dengue, and Zika infect human cells

Fri Dec 14, 2018
Nevan Krogan, PhD
Credit: 
Chris Goodfellow (Gladstone Institutes)

Nevan Krogan, PhD, senior author on the two studies and director of QBI

In a pair of recent studies, scientists at the Quantitative Biosciences Institute uncovered how Ebola, dengue, and Zika hijack human proteins to infect human cells, findings that point to new approaches for treating these diseases.

Research points to individualized treatments for curing TB

Tue Nov 20, 2018
Savic speaking at podium

Rada Savic, PhD, senior author on the study, presented her team's work on tuberculosis treatments at the 49th Union World Conference on Lung Health in The Hague, The Netherlands, in late October 2018.

Tuberculosis is usually treated with a six month regimen of daily antibiotics, but millions of patients do not recover from the disease during treatment. Rada Savic’s team showed that adjusting the duration of this regimen based on disease severity could lead to better outcomes.

Pages

Make a gift
We see a time when precise therapeutics—used safely and effectively—improve the health of people everywhere.
© 2002–2019 The Regents of the University of California